Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma

Cancer Science

Volumn 101, Issue 8, 2010, Pages 1913-1919

  Hasita, Horlad ^a,b   Komohara, Yoshihiro ^a   Okabe, Hirohisa ^b   Masuda, Toshiro ^b   Ohnishi, Koji ^a   Lei, Xiao F ^a   Beppu, Toru ^b   Baba, Hideo ^b   Takeya, Motohiro ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; CYTOKINE; GELATINASE A; INTERLEUKIN 10; MARKER; PARAFFIN; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A;

AGED; ANGIOGENESIS; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER PATIENT; CD4 LYMPHOCYTE COUNT; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENSITY; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MACROPHAGE ACTIVATION; MALE; NEOVASCULARIZATION (PATHOLOGY); OVERALL SURVIVAL; PHENOTYPE; POLARIZATION; POPULATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; SUPERNATANT;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; HUMANS; INTERLEUKIN-6; MACROPHAGE ACTIVATION; MACROPHAGES; PROGNOSIS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY;

EID: 77954855351     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01614.x     Document Type: Article

References (40)

1. Shirabe K, Shimada M, Harimoto N. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities. Surgery 2002, 131:S159-64.
2. Shirabe K, Shimada M, Tsujita E. Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis. Am J Surg 2004, 187:538-42.
3. Hanazaki K, Kajikawa S, Shimozawa N. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multi-variate analysis. Hepatogastroenterology 2002, 49:311-6.
4. Suzuki H, Isaji S, Pairojkul C, Uttaravichien T. Comparative clinico-pathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and Japan. J Hepatobiliary Pancreat Surg 2000, 7:206-11.
5. Isaji S, Kawarada Y, Taoka H, Tabata M, Suzuki H, Yokoi H. Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg 1999, 6:108-16.
6. DeOliveira ML, Cunningham SC, Cameron JL. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007, 245:755-62.
7. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
8. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macro-phages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006, 42:717-27.
9. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-8.
10. Hallam S, Escorcio-Correia M, Soper R, Schultheiss A, Hagemann T. Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol 2009, 219:143-52.
11. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-55.
12. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003, 73:209-12.
13. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006, 177:7303-11.
14. van Dongen M, Savage ND, Jordanova ES. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer 2009, [Epub ahead of print]
15. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008, 216:15-24.
16. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 2009, 59:300-5.
17. Jensen TO, Schmidt H, Moller HJ. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009, 27:3330-7.
18. Espinosa I, Beck AH, Lee CH. Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Am J Pathol 2009, 174:2347-56.
19. Kurahara H, Shinchi H, Mataki Y. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 2009, [Epub ahead of print]
20. Okabe H, Beppu T, Hayashi H. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009, 16:2555-64.
21. Nozaki Y, Yamamoto M, Ikai I. Reconsideration of the lymph node metastasis pattern (N factor) from intrahepatic cholangiocarcinoma using the International Union Against Cancer TNM staging system for primary liver carcinoma. Cancer 1998, 83:1923-9.
22. Aurello P, D'Angelo F, Rossi S. Classification of lymph node metastases from gastric cancer: comparison between N-site and N-number systems. Our experience and review of the literature. Am Surg 2007, 73:359-66.
23. Sica A, Larghi P, Mancino A. Macrophage polarization in tumour progression. Semin Cancer Biol 2008, 18:349-55.
24. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009, 86:1065-1073.
25. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008, 84:623-30.
26. Guan Y, Yu S, Zhao Z, Ciric B, Zhang GX, Rostami A. Antigen presenting cells treated in vitro by macrophage colony-stimulating factor and autoantigen protect mice from autoimmunity. J Neuroimmunol 2007, 192:68-78.
27. Kryczek I, Wei S, Zhu G. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007, 67:8900-5.
28. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008, 267:204-15.
29. Sasaki T, Isayama H, Nakai Y. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2009, 65:1101-1107.
30. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007, 110:1911-28.
31. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 2009, 284:34342-54.
32. Qian B, Deng Y, Im JH. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 2009, 4:e6562.
33. Hernandez L, Smirnova T, Kedrin D. The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12. Cancer Res 2009, 69:3221-7.
34. Robinson BD, Sica GL, Liu YF. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 2009, 15:2433-41.
35. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007, 117:1155-66.
36. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7:41-51.
37. Chen SH, Murphy DA, Lassoued W, Thurston G, Feldman MD, Lee WM. Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther 2008, 7:1994-2003.
38. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007, 178:2623-9.
39. Costantino L, Barlocco D. STAT 3 as a target for cancer drug discovery. Curr Med Chem 2008, 15:834-43.
40. Hussain SF, Kong LY, Jordan J. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007, 67:9630-6.